Background:

Pirinixil is a hypolipidemic agent of low toxicity.

Pirinixil is a hypolipidemic agent of low toxicity. Total cholesterol is reduced by Pirinixi in the spleen, kidney and heart of rats. Pirinixil decreases the estimated total body cholesterol approximately 40%[1]. Pirinixil increases plasma cholesterol levels significantly without affecting plasma triglycerides. Liver cholesterol and triglycerides are markedly reduced by Pirinixil, while combined plasma and liver lipid levels decrease approximately 20%. Liver HMG-CoA reductase activity is not affected, but cholesterol 7α-hydroxylase is significantly reduced by Pirinixil[2].

[1]. D’Atri G, et al. Clofibrate, pirinixil (BR 931) and WY-14,643 do not affect body cholesterol in Sprague-Dawley rats. Atherosclerosis. 1980 Nov;37(3):475-83. [2]. Kritchevsky D, et al. Increased plasma cholesterol and decreased body lipid levels in Wistar rats following pirinixil(BR 931) treatment. Pharmacol Res Commun. 1979 Jun;11(6):475-82.